Pulmicort (Budesonide Inhalation) - Summary

PULMICORT SUMMARY

Budesonide, the active component of PULMICORT FLEXHALER is a corticosteroid designated chemically as (RS)-11β, 16α, 17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde.

PULMICORT FLEXHALER is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of those patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.

PULMICORT FLEXHALER is NOT indicated for the relief of acute bronchospasm.

See all Pulmicort indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Pulmicort (Budesonide Inhalation)

Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. [2015]
remission in patients with ulcerative proctitis or ulcerative proctosigmoiditis... CONCLUSIONS: Budesonide rectal foam was well tolerated and more efficacious than

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. [2015]
budesonide MMX in patients with mild-to-moderate active UC... CONCLUSION: This pooled analysis showed that budesonide MMX 9 mg is efficacious,

Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double-blind, placebo-controlled study. [2013]
exacerbation of asthma... CONCLUSION: On the basis of nebulized short-acting bronchodilators, addition of

Safety and Tolerability of High-Dose Budesonide/Formoterol via Turbuhaler(R) in Japanese Patients with Asthma: A Randomized, Double-Blind, Crossover, Active Comparator-Controlled, Phase III Study. [2012.01.01]
Background: The use of budesonide/formoterol as both maintenance and reliever therapy in asthma is recommended in many countries; however, there are limited data available for the Asian patient population. Objective: This study aimed to evaluate the short-term safety and tolerability of a fixed high-dose combination of the inhaled corticosteroid budesonide and the long-acting beta(2)-adrenoceptor agonist formoterol with that of the beta(2)-agonist terbutaline for acute symptom relief in Japanese adults with persistent asthma who were already receiving a combination of budesonide/formoterol maintenance therapy...

Abatacept for Crohn's disease and ulcerative colitis. [2012]
modulator, in Crohn's disease (CD) and ulcerative colitis (UC) is unknown... CONCLUSIONS: The studies showed that abatacept is not efficacious for the

more studies >>

Clinical Trials Related to Pulmicort (Budesonide Inhalation)

Pulmicort Respules on Relapse Rates After Treatment in the ED [Withdrawn]
The purpose of this study is to see if the addition of budesonide to oral corticosteroids will result in a decrease in relapse rates compared to oral corticosteroids alone in children who are discharged from the ED after an asthma exacerbation. Secondly, that there will be an improvement in lung function, a decrease in beta-2 agonist use and an improvement in health-related quality of life compared to placebo.

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth [Recruiting]
Children with mild persistent asthma that have asthma symptoms once or twice a week and use a daily controller, while children with mild intermittent asthma rarely have asthma symptoms and do not use a daily controller. Inhaled corticosteroids are the standard treatment for mild peristent asthma. The purpose of this study is to measure children rate of growth while on different inhaled corticosteroids.

Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children [Completed]
A one year study comparing the safety and effectiveness of Pulmicort (0. 5mg strength given once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the evening) in children with asthma aged 2 to 8. If allocated to SINGULAR treatment, children aged between 2 and 5 will receive 4mg strength SINGULAR and those aged between 6 and 8 will receive 5mg strength SINGULAR.

Long-Term Safety of Symbicort in Asthmatic Children - SAPLING [Completed]

Adults With Moderate to Severe Asthma [Completed]
A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when given to asthma patients aged 12 years and above.

more trials >>

Reports of Suspected Pulmicort (Budesonide Inhalation) Side Effects

Asthma (88),  Dyspnoea (87),  OFF Label USE (83),  Drug Dose Omission (70),  Malaise (62),  Cough (33),  Chronic Obstructive Pulmonary Disease (29),  Drug Ineffective (24),  Pneumonia (23),  Dysphonia (18), more >>